Novare Capital Management LLC decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,224 shares of the biopharmaceutical company’s stock after selling 1,555 shares during the quarter. Novare Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,342,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Vanguard Group Inc. lifted its holdings in Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after buying an additional 333,685 shares during the period. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after buying an additional 2,367,864 shares during the period. Dodge & Cox lifted its holdings in Bristol-Myers Squibb by 1.6% during the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after buying an additional 459,271 shares during the period. Jennison Associates LLC lifted its holdings in Bristol-Myers Squibb by 16.2% during the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares during the period. Finally, Northern Trust Corp lifted its holdings in Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after buying an additional 910,496 shares during the period. 71.55% of the stock is currently owned by institutional investors.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.45 on Tuesday. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The firm has a market capitalization of $110,885.03, a PE ratio of 22.57, a PEG ratio of 2.08 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period last year, the company posted $0.63 EPS. The business’s quarterly revenue was up 3.9% on a year-over-year basis. research analysts predict that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.37%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 271.19%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.